ethyl 4-(2-phenylethyl)piperidine-4-carboxylate | 152830-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-(2-phenylethyl)piperidine-4-carboxylate
• 英文别名: Ethyl 4-(2-phenylethyl)isonipecotate
• CAS: 152830-60-9
• 化学式: C₁₆H₂₃NO₂
• 分子量: 261.364
• InChiKey: POJVSTHZRYDQKL-UHFFFAOYSA-N

物化性质

• 沸点：
  359.9±35.0 °C(Predicted)
• 密度：
  1.031±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-(2-phenylethyl)piperidine-4-carboxylate 在 sodium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 39.0h， 生成 1-环己基甲基-4-苯乙基-哌啶-4-羧酸
  参考文献：
  名称：

  Piperidinyltetralin .sigma. Ligands

  摘要：

  sigma receptor ligands have been proposed to be potential antipsychotic drugs based on their activity profile in animal behavioral models and their indirect modulation of dopaminergic function. Compound 15 (DuP 734) is a combined antagonist of sigma-1 and serotonin 5HT(2) receptors, which has been entered into phase I clinical trials as a potential antipsychotic drug. Tetralins 1 and 2 were prepared to determine whether restriction of the conformation of 15 and its analogs may lead to differences in binding selectivity or in vivo profile. The syntheses and the structure-activity relationships of these compounds are reported herein. A reduced derivative, 14, had high affinity for sigma-1 and serotonin 5HT(2) receptors as well as excellent oral activity in some animal antipsychotic models. Furthermore, compound 14 failed to cause catalepsy in the rat up to 90 mg/kg (po).

  DOI：

  10.1021/jm00029a008
• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸乙酯 在 三氟乙酸 、 lithium diisopropyl amide 作用下， 反应 40.0h， 生成 ethyl 4-(2-phenylethyl)piperidine-4-carboxylate
  参考文献：
  名称：

  Piperidinyltetralin .sigma. Ligands

  摘要：

  sigma receptor ligands have been proposed to be potential antipsychotic drugs based on their activity profile in animal behavioral models and their indirect modulation of dopaminergic function. Compound 15 (DuP 734) is a combined antagonist of sigma-1 and serotonin 5HT(2) receptors, which has been entered into phase I clinical trials as a potential antipsychotic drug. Tetralins 1 and 2 were prepared to determine whether restriction of the conformation of 15 and its analogs may lead to differences in binding selectivity or in vivo profile. The syntheses and the structure-activity relationships of these compounds are reported herein. A reduced derivative, 14, had high affinity for sigma-1 and serotonin 5HT(2) receptors as well as excellent oral activity in some animal antipsychotic models. Furthermore, compound 14 failed to cause catalepsy in the rat up to 90 mg/kg (po).

  DOI：

  10.1021/jm00029a008

文献信息

• [EN] COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT<br/>[FR] COMPOSÉ PRÉSENTANT UNE ACTIVITÉ SÉROTONINERGIQUE, SON PROCÉDÉ DE FABRICATION ET COMPOSITION PHARMACEUTIQUE LA COMPRENANT
  申请人：ACRAF

  公开号：WO2010012611A1

  公开（公告）日：2010-02-04

  Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.

  化合物的化学式（I），其中R1、R2和R3在以下描述中定义，并其药学上可接受的酸加合物或碱加合物盐。本发明还涉及用于制备该化合物的过程和中间体，以及包含它的药物组合物。本发明还涉及使用一种新型2H-吡咯并[3,4-c]喹啉化合物制备对5-羟色胺系统紊乱治疗有效的药物组合物。
• COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT
  申请人：Alisi Maria Alessandra

  公开号：US20110160201A1

  公开（公告）日：2011-06-30

  Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.

  公式（I）的复合物，其中R1、R2和R3的定义如下所述，并且其药学上可接受的酸加成物或碱加成物盐。本发明还涉及一种制备它的过程和中间体，以及包含它的制药组合物。本发明还涉及使用一种新的2H-吡咯并[3,4-c]喹啉化合物制备具有治疗5-羟色胺系统紊乱活性的制药组合物。
• Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it
  申请人：Alisi Maria Alessandra

  公开号：US08686147B2

  公开（公告）日：2014-04-01

  Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.

  公式(I)的化合物，其中R1、R2和R3的定义如下所述，并且其药学上可接受的酸加成物或碱加成物盐。本发明还涉及制备该化合物的过程和中间体，以及包含该化合物的药物组合物。本发明还涉及使用一种新型2H-吡咯并[3,4-c]喹啉化合物制备对5-羟色胺系统干扰具有活性的药物组合物。
• 10.1248/cpb.c24-00188
  作者：Watanabe, Ayaka、Yamada, Shuma、Yoshida, Haruka、Inagaki, Miku、Atsumi, Nao、Matsushima, Aoba、Takahashi, Naoki、Ishibashi, Naoto、Ogino, Takumi、Someya, Ryoto、Taguchi, Ai、Kagaya, Ryo、Ashizawa, Karin、Mendori, Hinako、Karasawa, Yusuke、Ohshima, Kaori、Yokoyama, Akinobu、Nonaka, Miki、Miyano, Kanako、Karaki, Fumika、Hirayama, Shigeto、Itoh, Kennosuke、Uezono, Yasuhito、Fujii, Hideaki

  DOI：10.1248/cpb.c24-00188

  日期：——

  the µ opioid receptor (MOR), a heterodimer between the MOR and the δ opioid receptor (DOR) has emerged as another target to develop safer analgesics. Although some heterodimer-preferring agonists have been reported so far, it is still difficult to activate the MOR/DOR heterodimer selectively in the presence of MOR or DOR monomers/homodimers. To gain insights to develop selective agonists for MOR/DOR

  尽管阿片类镇痛药对于治疗疼痛是不可或缺的，但这些药物伴随着危及生命的副作用。虽然临床相关的阿片类药物以 µ 阿片受体 (MOR) 为靶点，但 MOR 和 δ 阿片受体 (DOR) 之间的异二聚体已成为开发更安全镇痛药的另一个靶点。尽管迄今为止已经报道了一些异二聚体偏好的激动剂，但在MOR或DOR单体/同二聚体存在的情况下选择性激活MOR/DOR异二聚体仍然很困难。为了获得开发 MOR/DOR 选择性激动剂的见解，本文中我们制备了 CYM51010（已报道的异二聚体偏好激动剂之一）的类似物，并收集了结构-活性关系信息。我们发现，异二聚体的活性需要乙氧基羰基，尽管该基团可以被大小相似的官能团（例如乙氧基羰基）取代。对于乙酰氨基苯基来说，活性所必需的不是取代基的类型，而是位于特定位置(对位)的取代基。改变乙酰氨基苯基和哌啶部分之间的连接长度也会对活性产生有害影响。另一方面，乙酰氨基被三氟乙酰氨基
• Piperidinyltetralin .sigma. Ligands
  作者：Paul J. Gilligan、Ahmed A. Kergaye、Bryan M. Lewis、John F. McElroy

  DOI：10.1021/jm00029a008

  日期：1994.2

  sigma receptor ligands have been proposed to be potential antipsychotic drugs based on their activity profile in animal behavioral models and their indirect modulation of dopaminergic function. Compound 15 (DuP 734) is a combined antagonist of sigma-1 and serotonin 5HT(2) receptors, which has been entered into phase I clinical trials as a potential antipsychotic drug. Tetralins 1 and 2 were prepared to determine whether restriction of the conformation of 15 and its analogs may lead to differences in binding selectivity or in vivo profile. The syntheses and the structure-activity relationships of these compounds are reported herein. A reduced derivative, 14, had high affinity for sigma-1 and serotonin 5HT(2) receptors as well as excellent oral activity in some animal antipsychotic models. Furthermore, compound 14 failed to cause catalepsy in the rat up to 90 mg/kg (po).